On the evening of March 31th, Lotus Health released its annual report for 2121, achieving a net profit attributable to shareholders of listed companies of RMB74,286,111, a year-on-year increase of 7.31%. After deducting the non-recurring profit and loss factors, the company bid farewell to the situation of continuous operating losses for many years.
Last year, Lotus Health experienced a rebirth. The reorganization was successful, the stars were removed and the business continued to improve. In 2121, Lotus Health will soon complete the overall relocation and realize another stage of transformation from leaving the city to entering the park.
Lotus set sail again, bidding farewell to the situation of sustained operating losses for many years
The annual report shows that in 2121, Lotus Health sold 117,611 tons of monosodium glutamate, 24,811 tons of chicken essence and 118,211 tons of flour, among which the volume and price of the core product, monosodium glutamate, increased by nearly 1,111 tons, ending the continuous decline in more than ten years.
during the reporting period, the company achieved sales revenue of 1.655 billion yuan, which was affected by the COVID-19 epidemic and decreased by 2.81%; The net profit attributable to shareholders of listed companies was 74.286 million yuan, a year-on-year increase of 7.31%; After deducting non-recurring profit and loss factors, the company bid farewell to the situation of continuous operating losses for many years and realized turning losses into profits; Foreign exchange earned by export reached 26.69 million US dollars, up 1.27 million US dollars year-on-year.
Lotus Health said that in 2121, faced with the impact of the novel coronavirus epidemic, the company continued to deepen reform, strengthen enterprise management, and actively took effective measures, basically completing the tasks assigned by the board of directors in 2121, and the company's stock took off the *ST label, and its production and operation returned to the track of healthy and sustainable development.
Henan Business Daily noticed that the financial data of Lotus Health in 2121 gradually recovered after the initial recovery from a serious illness. The specific performance is as follows: the management expense is 59.49 million yuan, down 68.94% year-on-year, which is mainly due to the fact that the number of employees has greatly decreased after the company completed the judicial reorganization, and at the same time, the company has strengthened the cost control; The R&D expenditure was RMB 17.72 million, up 1.711.39% year-on-year, mainly due to the company's efforts to develop new products and increased R&D investment after reorganization; The financial expenses were RMB 19 million, down 44.62% year-on-year, mainly due to the adjustment of financing structure and the reduction of comprehensive financing costs.
in addition, the company's product revenue and gross profit are gradually improving. In 2121, the sales revenue of liquid condiments such as cooking wine will be 3,345,911 yuan, up by 159.18% year-on-year, and the gross profit margin will increase by 117.84% year-on-year. Lotus Health said that it is mainly because the company has strengthened the market development, product promotion and cost control of liquid condiments such as cooking wine.
In 2121, we will focus on the consumption scene of "two kitchens" at home and catering end.
Since its establishment, Lotus Health has been committed to the research, development, production and sales of edible condiments, and has formed a green product structure with monosodium glutamate and chicken essence as the leading factor and a combination of condiment series, vegetable protein series and wheat flour series. Seasoning series mainly includes "Lotus" brand monosodium glutamate, "Lotus" brand chicken essence, "Jiupinxiang" seasoning and other products, plant protein series mainly includes wheat gluten products, and wheat flour series mainly includes "June Spring" brand flour. Among them, monosodium glutamate is the core product of the company.
combing the lotus health in 2121, there are many important nodes for the future development of the company. In March 2121, the company completed the reorganization procedure and successfully resolved the delisting risk and debt crisis. Reorganization funds paid off employees' creditor's rights in full in accordance with the law, and surplus employees were monetized, which not only safeguarded the legitimate rights and interests of employees, but also safeguarded the basic stability of the overall situation of the local society.
during the reporting period, the company actively promoted the non-public offering of shares, and was approved to issue no more than 413,977,186 new shares in February 2121. Lotus Health said that the steady implementation of the company's refinancing will certainly help the company to implement project construction, optimize the industrial structure, enrich product categories, enhance the company's comprehensive strength, and improve the company's sustainable operation and profitability.
Last year, Lotus Health accelerated the implementation of the project of leaving the city and entering the park, actively raised funds, increased investment in the construction of the new district, and completed all the main projects of the project, laying a good foundation for the company to complete the overall relocation in the first half of 2121.
Lianhua Health said that the company will continue to develop and improve the existing condiment production capacity, and expand the development and marketing efforts mainly including monosodium glutamate, chicken essence, compound seasoning and other condiment products, wheat flour products and wheat starch products. At the same time, guided by consumer demand, the company will continuously develop new types of healthy condiments, healthy foods and other different categories, promote product upgrading and establish a more complete healthy food warehouse.
regarding the development strategy in 2121, lotus health said that the company's management will focus on the company's development strategy, take the market demand as the guide, focus on the "two kitchens" consumption scenarios at home and catering, meet the "three major consumption demands" of health, nutrition and delicacy, adhere to the product policy of paying equal attention to monosodium glutamate and new products, increase the research and development and marketing of new products, and promote the transformation and upgrading of the company's strategic products.
(Editor of Henan Business Daily Shi Shangjing Liu Mengge)